• Crossject Newsletter N°3

    -Supergenerics : lastest developments
    -Stronger Intellectual Property Position
    -"Inventions and men", M6 - 17/06/2015
    -Positive feedbacks from the USA
    -Next event

    Read more
  • Crossject confirms the development plan for ZENEO® Sumatriptan

    A serie of good news for Crossject announcing the confirmation of the clinical and regulatory development plan for ZENEO® Sumatriptan as well as the start of discussions with the FDA.

    Read more


  • 07/10/2015

    Crossject will be present at BIO Pharm America 2015

    Meet us in Boston, September 15th to 17th, during the 2015 BIO Pharm America, the biotech industry partnerships event.
    Contact Tim Muller: or  / Mobile +33 (0)645523540 / skype id: timotheemuller

    Read more
  • 06/10/2015

    Crossject will be present at The French Life Science days in New-York

    The second edition of the « French Life Science Days » aims to bring together listed French companies and North American financial community in order to allow innovative companies to promote their business to Healthcare investors in the United-States.

    Read more


Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos